Expression levels of ADGRG6 mRNA in PAAD and clinical subgroups (GEPIA and UALCAN). (A) Comparison of ADGRG6 mRNA expression between PAAD tissues (n = 179) and normal tissues (n = 171) from the GEPIA database (TCGA + GTEx). (B–I) UALCAN-based subgroup analysis of ADGRG6 expression levels in PAAD samples stratified by sex (B), pancreatitis status (C), age (D), drinking habits (E), diabetes status (F), tumor grade (G), lymph node metastasis (H), and TP53 mutation status (I). The “normal” group in UALCAN (n = 4) includes adjacent non-tumor tissues, without subgroup annotations. The comparison to the “normal” group in the UALCAN analysis should be interpreted with caution due to the small size of the normal cohort (n = 4). “Drinking status” data is incomplete (missing in 80 samples), and comparisons among subgroups should be interpreted cautiously. Subtype descriptions of “Tumor Grade”: Grade 1-Well differentiated (low grade), Grade 2-Moderately differentiated (intermediate grade), Grade 3-Poorly differentiated (high grade), Grade 4-Undifferentiated (high grade). Pathologic descriptions of “Nodal Metastasis Status”: N0-No regional lymph node metastasis, N1-Metastases in 1 to 3 axillary lymph nodes. Data are presented as Mean ± SD. Statistical analysis was performed using Student’s t-test for two-group comparisons and one-way ANOVA followed by Bonferroni’s post hoc test. “*” indicates comparison with the control group; “#” indicates significance between experimental groups (* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05, ## p < 0.01).
|
